In the past, the life expectancy of men with metastaticprostate cancerwas 2-3 years. Butwith advancements in medicine and care, the life expectancy of men with metastatic prostatecancerhas increased to about 5-6 years. The 5-year survival rate of metastatic prostate canceris 28%, which is m...
M. (2014). Overtreatment of men with early-stage prostate cancer and limited life expectancy . Cancer 120 , 3592–3594. 10.1002/cncr.28927 [ Cross Ref ]Matthew R. Danzig, James M. McKiernan. (2014) Overtreatment of men with early-stage prostate cancer and limited life expectancy. Cancer ...
Aparicio, J. et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).Ann. Oncol.25, 2173–2178 (2014). ArticleCASPubMedGoogle Scholar Tandstad, T. et al. Management of...
MCC-Spain was born as a case–control study on colorectal, breast, prostate and gastric cancers and chronic lymphoid leukaemia16. Later on, the colorectal, breast and prostate cancer cases recruited in the case–control phase were incepted in three cancer-specific cohorts in order to ascertain cl...
We previously reported that the pattern of PBC progression can be classified into three different types: (1) slowly progressive, which does not influence life expectancy; (2) progressive, which proceeds to liver cirrhosis and/or portal hypertension, but rarely to jaundice and end-stage hepatic ...
PD13-03OVERTREATMENT OF MEN WITH LIMITED LIFE EXPECTANCY FOR EARLY STAGE PROSTATE CANCER HAS INCREASED IN THE ACTIVE SURVEILLANCE ERAdoi:10.1097/01.JU.0001009552.62973.71.03Timothy J. DaskivichJohn HeardI-Chun ThomoasJohn LeppertWolters KluwerThe Journal of Urology...
Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer 2014;1-9.Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, et al. Variation in treatment associated with life expectancy in a population-based...
(Supplementary Fig.2). Here, only three factors that are considered to be most significant in developing clinically applicable multigene assay in a routine clinical setting are shown: (1). Hazard ratios for stratifying performance; (2). Validation sample size for statistical robustness; and (3)....
(TNI). This analysis of a prospective cohort includes PET-staged patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24–30Gy between 1999 and 2017. Fifteen ...
advanced-stage lung cancer;quality of life;functional status;individualized management 1. Background Lung cancer remains the leading cause of cancer-related death in the United States and makes up 12–13% of all cancer diagnoses, second to prostate cancer in men and breast cancer in women [1]...